PMC:7309518 / 342-698 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":198,"end":206},"obj":"Body_part"},{"id":"T2","span":{"begin":212,"end":217},"obj":"Body_part"},{"id":"T3","span":{"begin":218,"end":229},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma65132"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma82780"}],"text":"rns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the cont"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":212,"end":217},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0001021"}],"text":"rns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the cont"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T10","span":{"begin":55,"end":58},"obj":"Disease"},{"id":"T11","span":{"begin":77,"end":85},"obj":"Disease"},{"id":"T12","span":{"begin":249,"end":257},"obj":"Disease"},{"id":"T13","span":{"begin":268,"end":299},"obj":"Disease"},{"id":"T14","span":{"begin":291,"end":299},"obj":"Disease"},{"id":"T16","span":{"begin":301,"end":304},"obj":"Disease"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0016098"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0008054"},{"id":"A15","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0021167"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0009722"},{"id":"A17","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0016098"}],"text":"rns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the cont"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T2","span":{"begin":212,"end":217},"obj":"http://purl.obolibrary.org/obo/UBERON_0001021"}],"text":"rns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the cont"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":198,"end":206},"obj":"Chemical"},{"id":"T2","span":{"begin":218,"end":229},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_33563"}],"text":"rns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the cont"}

{"project":"LitCovid-PubTator","denotations":[{"id":"15","span":{"begin":77,"end":85},"obj":"Disease"},{"id":"16","span":{"begin":186,"end":191},"obj":"Disease"},{"id":"17","span":{"begin":249,"end":257},"obj":"Disease"},{"id":"18","span":{"begin":268,"end":299},"obj":"Disease"},{"id":"19","span":{"begin":310,"end":326},"obj":"Disease"}],"attributes":[{"id":"A15","pred":"tao:has_database_id","subj":"15","obj":"MESH:C000657245"},{"id":"A16","pred":"tao:has_database_id","subj":"16","obj":"MESH:C000657245"},{"id":"A17","pred":"tao:has_database_id","subj":"17","obj":"MESH:C000657245"},{"id":"A18","pred":"tao:has_database_id","subj":"18","obj":"MESH:D020721"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"MESH:D001927"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"rns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the cont"}

{"project":"LitCovid-sentences","denotations":[{"id":"T7","span":{"begin":40,"end":47},"obj":"Sentence"},{"id":"T8","span":{"begin":48,"end":230},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"rns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the cont"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T4","span":{"begin":291,"end":299},"obj":"Phenotype"},{"id":"T5","span":{"begin":310,"end":326},"obj":"Phenotype"}],"attributes":[{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0100614"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0001298"}],"text":"rns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the cont"}